In a 2019 clinical study, Farkas et al. hypothesized that the expression of TLR3 is an essential process for maintaining endothelial cell homeostasis and protection, and the activation of TLR3 with drugs is a potential therapeutic target in the treatment of pulmonary arterial hypertension [21]. This evidence concerns the gene TLR3 and pulmonary arterial hypertension.